Keros Therapeutics (NASDAQ:KROS) Director Nima Farzan Sells 2,625 Shares

Keros Therapeutics, Inc. (NASDAQ:KROS) Director Nima Farzan sold 2,625 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total transaction of $28,166.25. Following the transaction, the director directly owned 9,767 shares in the company, valued at approximately $104,799.91. The trade was a 21.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Keros Therapeutics Trading Down 2.9%

Shares of Keros Therapeutics stock opened at $10.00 on Tuesday. The company’s fifty day simple moving average is $11.31 and its two-hundred day simple moving average is $15.10. The company has a market cap of $197.90 million, a P/E ratio of -3.32 and a beta of 0.94. Keros Therapeutics, Inc. has a 12-month low of $9.79 and a 12-month high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($1.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.19). The company had revenue of $0.37 million for the quarter, compared to analysts’ expectations of $1.93 million. Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 17.04%. Analysts predict that Keros Therapeutics, Inc. will post -5.19 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on KROS shares. Wall Street Zen downgraded shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Weiss Ratings downgraded shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 15th. Finally, Wells Fargo & Company reduced their target price on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, March 5th. Three equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Keros Therapeutics has a consensus rating of “Hold” and a consensus price target of $20.40.

Institutional Trading of Keros Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company grew its position in shares of Keros Therapeutics by 8.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock worth $166,000 after buying an additional 988 shares during the period. UBS Group AG grew its position in shares of Keros Therapeutics by 1.1% in the 3rd quarter. UBS Group AG now owns 103,864 shares of the company’s stock worth $1,643,000 after buying an additional 1,091 shares during the period. Strs Ohio grew its position in shares of Keros Therapeutics by 3.9% in the 4th quarter. Strs Ohio now owns 29,300 shares of the company’s stock worth $597,000 after buying an additional 1,100 shares during the period. Caitong International Asset Management Co. Ltd boosted its stake in Keros Therapeutics by 254.6% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after purchasing an additional 1,166 shares in the last quarter. Finally, Financial Management Professionals Inc. bought a new position in Keros Therapeutics in the 4th quarter worth about $29,000. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.